|University of Washington Press Release about TPAD2.0||Mike MacCoss||2020-11-04 10:45:01|
A major scientific effort is underway to characterize the proteins in the cerebrospinal fluid to improve diagnostics and clinical monitoring assays, and discover potential therapies, for Alzheimer’s disease.
Several research labs at the University of Washington School of Medicine and Stanford University are pooling their protein science expertise in this program. Their area – proteomics -- is the large-scale analysis of proteins, including their abundance, structure, and function in a biological system. They are eager to apply recent advances in this growing field toward improving our ability to monitor disease and response to treatment for Alzheimer’s disease patients.
This Next Generation Translational Proteomics for Alzheimer’s and Related Dementias program is funded by a grant expected to total $15.9 million over five years from the National Institute on Aging at the National Institutes of Health.